MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.

@article{An2014METAI,
  title={MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.},
  author={Xin An and Fang Wang and Qiong Shao and Fenghua Wang and Zhiqiang Wang and Cui Ming Chen and Cong Li and Hui-yan Luo and Dongsheng Zhang and Ruihua Xu and Yuan-hua Li},
  journal={Cancer},
  year={2014},
  volume={120 5},
  pages={675-82}
}
BACKGROUND Several large studies have reported an extremely low incidence of MET gene amplification (GA) in patients with radically resected gastric cancer. This study was conducted to evaluate the prevalence and prognostic role of MET in patients with recurrent=metastatic gastric cancer who received chemotherapy. METHODS MET GA and protein expression of recurrent=metastatic gastric cancer samples were evaluated by fluorescence in situ hybridization and immunohistochemistry (IHC… CONTINUE READING
22 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…